Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmanex seeking court order to allow red yeast rice imports.

This article was originally published in The Tan Sheet

Executive Summary

PHARMANEX PRELIMINARY INJUNCTION HEARING SET FOR JUNE 15 in Salt Lake City federal court. At the hearing, the court will consider a request by Pharmanex for a preliminary injunction against FDA that would allow the company to resume import of Chinese red yeast rice for Cholestin at least until a final court decision is reached on whether the product is in compliance with the law. Pharmanex went back to court following FDA's May 20 decision that Cholestin is an unapproved new drug and may not be marketed as a dietary supplement.
Advertisement

Related Content

Pyridoxamine Supplement Sale Should Cease Following IND Filing - Petition
Pyridoxamine Supplement Sale Should Cease Following IND Filing - Petition
Pyridoxamine Supplement Sale Should Cease Following IND Filing - Petition
Pharmanex Cholestin Bar For Healthy Cholesterol Levels Launching
Pharmanex Cholestin Bar For Healthy Cholesterol Levels Launching
Pharmanex Cholestin Bar For Healthy Cholesterol Levels Launching
Drug Industry Incentives Out Of DSHEA Purview - Pharmanex Brief
Drug Industry Incentives Out Of DSHEA Purview - Pharmanex Brief
Drug Industry Incentives Out Of DSHEA Purview - Pharmanex Brief
Cholestin Decision Threat To "Pioneer" Drug Exclusivity Cited In FDA Appeal

Topics

Advertisement
UsernamePublicRestriction

Register

PS088474

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel